Soligenix, Inc. SNGX 深 沪
交易中 05-11 11:50:35 美东时间
0.2866
-0.006
-2.18%
华盛通- 最 高0.339
- 今 开0.29
- 成交量 39.25万股
- 最 低 0.2825
- 昨 收 0.293
- 总市值 1.23万
- 52周最高 6.2299
- 市盈率 静 --
- 换手率 911.81%
- 52周最低 0.2825
- 委 比 0.00%
- 总股本 4.31万
- 历史最高 14.8299
- 量 比 1.31
- 振 幅 19.28%
- 历史最低 0.28
- 每 手 1
- 风险率 0.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Soligenix Q1 EPS $(0.28), Inline
Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is a 73.58 percent increase over losses of $(1.06) per share from the same period last year.
05-08 19:38
Crude Oil Gains Over 3%; General Motors Earnings Top Views
US stocks down, NASDAQ falls over 1% on Tuesday. Dow up 0.20%, NASDAQ down 1.24%, S&P 500 down 0.65%. GM reports better-than-expected Q1 results.
04-29 00:35
Dow Gains 150 Points; Coca-Cola Posts Upbeat Earnings
US stocks mixed with Dow up 150 pts. Dow up 0.27%, NASDAQ down 1.06%, S&P 500 down 0.52%. Energy shares up 1.7%. Coca-Cola beats earnings & raises guidance. Baiya Int'l up 126%, Nexera up 63%, Aterian up 35%. Soligenix down 64%, Vistance down 51%, Erasca down 49%. Oil up 3.3%, gold down 2.3%, silver down 3.4%, copper down 0.7%. European markets mixed. Asian markets lower. US home prices increase, private-sector jobs report coming.
04-28 21:49
Watching Soligenix; Zacks Small-Cap Research Gives Stock $25.00 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_03122026_SNGX_Bautz.pdf
03-12 22:06
Soligenix's SGX945 (Dusquetide) Receives Promising Innovative Medicine Designation In U.K. For Behçet's Disease
Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced
03-10 19:35
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Inspira Technologies Oxy (NASDAQ:IINN) shares increased by 25.9% to $0...
02-09 20:05
Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel
Soligenix reports positive Phase 2a extension results for SGX302 gel in psoriasis, showing improved skin scores and strong tolerability.
2025-12-18 02:23
Soligenix Will Be Issued U.S. Patent Number 12,097,291 Tomorrow Titled "Thermostable Vaccine Compositions And Methods Of Preparing Same"
https://patentcenter.uspto.gov/applications/17537110/ifw/docs
2024-09-24 03:58
